119 / 1835
•
Prognosis of r&r HL still to be improved
•
DHAP or other reinduction followed by BEAM and ASCT standard in
relapsed lymphoma; intensification not helpful (HDR2)
•
BV effective and well tolerated; currently being evaluated in combination
with other drugs
•
Anti-PD1
´
s represent a new class of drugs showing very promising
activity in r/r lymphoma
•
GHSG to conduct trials with anti-PD1
´
s in cHL (early favorable,
unfavorable, abscopal)
•
Can new drugs replace radio- or chemotherapy in lymphoma?
Relapsed and refractory Lymphoma
Summary